Most recent by Jamile’ Wakim-Fleming, MD, FACG, FAASLD
FDA grants fast track designation to Merck’s efinopegdutide for treatment of NASH
The FDA granted fast track designation to efinopegdutide for the treatment of nonalcoholic steatohepatitis, according to a manufacturer’s press release.
Hepatologists, gastroenterologists lead NASH diagnosis yet ‘underdiagnosis’ persists
Gastroenterologists and hepatologists were leaders in nonalcoholic steatohepatitis diagnosis and viewed as primary coordinators of care, but the condition is still underdiagnosed and undertreated overall, noted data in BMC Gastroenterology.
Resmetirom ‘has potential to be first medication approved’ for patients with NASH
LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.
Unrecognized alcoholic hepatitis linked to higher mortality, hospitalization
SAN DIEGO — A significant proportion of alcoholic hepatitis cases remain unrecognized and correlate with higher 30-day mortality, hospital length of stay and ICU admission, according to results presented at Digestive Disease Week 2022.
NASH resolves, fibrosis improves in 22% treated with growth factor analogue
Fibroblast growth factor 19 analogue aldafermin showed dose- and duration-dependent reduction in liver fat with resolution of non-alcoholic steatohepatitis in more than one-fifth of cases, according to a presenter at the Digital International Liver Congress.
Millennials, fatty liver predicted to feed cirrhosis diagnoses by 2040
By 2040, researchers predict 75% of cirrhosis cases in North America will be due to nonalcoholic fatty liver disease with a nearly 350% increase in women born after 1980, according to a presenter at the Digital International Liver Conference.